News

A Thai doctor issued a warning after a patient injected sperm into his body in an attempt to treat back pain, leading to the ...
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...
Company News Published 06/20/2025, 01:22 PM 0 Argenx receives EU approval for VYVGART subcutaneous injection HALO -0.36% ...
SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $6.5 billion biotech company with exceptional financial health according to InvestingPro metrics, announced today that argenx has received ...
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
News release. Merck. March 27, 2025. Accessed May 25, 2025. https://bit.ly/43dSAQz 2. Steinzor P. FDA approves first subcutaneous nivolumab injection in most solid tumors. AJMC. January 2, 2025.